Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma

British Journal of Cancer

Volumn 114, Issue 4, 2016, Pages 444-453

  Carter, Julia H ^a   Deddens, James A ^b   Spaulding Iv, Nelson Reed ^c   Lucas, Denise ^a   Colligan, Bruce M ^a   Lewis, Thomas Grant ^a   Hawkins, Elyse ^a   Jones, Jordan ^a   Pemberton, Jackson O ^d   Douglass, Larry E ^a   Graff, Jeremy R ^e,f  

^a Wood Hudson Cancer Research Laboratory   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c University of Louisville School of Medicine   (United States)

^d St Elizabeth Healthcare   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Biothera Pharmaceutical Inc   (United States)

Author keywords

eIF4E; malignant melanoma; malignant progression; phospho eIF4E; survival

Indexed keywords

INITIATION FACTOR 4E; SERINE; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION; RETROSPECTIVE STUDY;

ADULT; BIOMARKERS, TUMOR; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; PHOSPHORYLATION; RETROSPECTIVE STUDIES; SERINE;

EID: 84962440765     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.450     Document Type: Article

References (43)

1. Altman JK, Szilard A, Konicek BW, Iversen PW, Kroczynska B, Glaser H, Sassano A, Vakana E, Graff JR, Platanias LC. (2013). Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood. 121: 3675-3681.
2. Bastian BC. (2014). The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 9: 239-271.
3. Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Desaubry L, Robert C, Vagner S. (2014). eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 513: 105-109.
4. Chin L, Merlino G, DePinho RA. (1998). Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12: 3467-3481.
5. Cope CL, Gilley R, Balmanno K, Sale MJ, Howarth KD, Hampson M, Smith PD, Guichard SM, Cook SJ. (2014). Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J Cell Sci. 127: 788-800.
6. Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, Tseng HY, Jin L, Rizos H, Hersey P, Zhang XD. (2014). Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. J Invest Dermatol. 134: 488-497.
7. Duband JL, Monier F, Delannet M, Newgreen D. (1995). Epithelium-mesenchyme transition during neural crest development. Acta Anat. 154: 63-78.
8. Elder DE, Murphy GF. (2010). Melanocytic Tumors of the Skin (AFIP Atlas of Tumor Pathology, Fourth Series Fascicle). American Registry of Pathology: Washington DC, USA
9. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. (2010). eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA. 107: 14134-14139.
10. Gilbert SF. (2000). Developmental Biology, 6th edn. Sinauer Associates: Sunderland, MA, USA
11. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. (1999). Regulation of 4E- BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13: 1422-1437.
12. Graff JR, Boghaert ER, De Benedetti A, Tudor DI, Zimmer CC, Chan SK, Zimmer SG. (1995). Reduction of translation initiation factor 4E decreases the malignancy of ras-Transformed cloned rat embryo fibroblasts. Int J Cancer. 60: 255-263.
13. Graff JR, Konicek BW, Carter JH, Marcusson EG. (2008). Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68: 631-634.
14. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, Hurst BM, Deddens JA, Neubauer BL, Stancato LF, Carter HW, Douglass LE, Carter JH. (2009). eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 69: 3866-3873.
15. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG. (2007). Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 117: 2638-2648.
16. Gray-Schopfer V, Wellbrock C, Marais R. (2007). Melanoma biology and new targeted therapy. Nature. 445: 851-857.
17. Haqq C, Nosrati M, Sudilosvsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller 3rd JR, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M. (2005). The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 102: 6092-6097.
18. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, Andre V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. (2011). A phase I dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide Ly2275796 in patients with advanced cancer. Clin Cancer Res. 17: 6582-6591.
19. Hsieh AC, Liu V, Edlin MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. (2012). The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485: 55-61.
20. Ilic N, Utermark T, Widlund HR, Roberts TM. (2011). PI3K-Targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA. 108: 699-708.
21. Jacobson BA, Thumma SC, Jay-Dixon J, Patel MR, Kroening KD, Kratzke MG, Etchison RG, Konicek BW, Graff JR, Kratzke RA. (2013). Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide. PLoS One. 8: 1-11.
22. Jaeger J, Koczan D, Thiesen H-J, Ibrahim SM, Gross G, Spang R, Kunz M. (2007). Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res. 13: 806-815.
23. Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE. (1995). Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem. 270: 14597-14603.
24. Knauf U, Tschopp C, Gram H. (2001). Negative regulation of protein translation by mitogen-Activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol. 21: 5500-5511.
25. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR. (2011). Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 71: 1849-1857.
26. Lian CG, Mihm MC Jr. (2014). Skin cancer. In: World Cancer Report 2014, Stewart BW, Wild CP (eds). International Agency for Research on Cancer World Health Organization: Lyon, France, pp 495-502.
27. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. (2009). Increasing burden of melanoma in the United States. J Invest Dermatol. 129: 1666-1674.
28. O'Reilly KE, Warycha M, Davies MS, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. (2009). Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res. 15: 2872-2878.
29. Pelletier J, Graff J, Ruggero D, Sonenberg N. (2015). Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 75: 250-263.
30. Ramon YCS, De Mattos-Arruda L, Sonenberg N, Cortes J, Peg V. (2014). The intra-Tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin Tranl Oncol. 16: 937-941.
31. Rinkler-Schaeffer CW, Austin V, Zimmer S, Rhoads RF. (1992). Ras transformation of cloned rat fibroblasts results in increased rates of protein synthesis and phosphorylation of eukaryotic initiation factor 4E. J Biol Chem. 267: 10659-10664.
32. Robichaud N, Del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH, Furic L, Larsson O, Muller WJ, Miller WH, Sonenberg N. (2014). Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 34: 2032-2042.
33. Siegel R, Ma J, Zou Z, Jemal A. (2014). Cancer Statistics, 2014. Ca Cancer J Clin. 64: 9-29.
34. Silvera D, Formenti SC, Schneider RJ. (2010). Translational control in cancer. Nat Rev Cancer. 10: 264-266.
35. Soengas MS, Lowe SW. (2003). Apoptosis and melanoma chemoresistance. Oncogene. 22: 3138-3151.
36. Topisirovic I, Ruiz-Gutierrez M, Borden KL. (2004). Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 64: 8639-8642.
37. Tschopp C, Knauf U, Brauchle M, Zurini M, Ramage P, Glueck D, New L, Han J, Gram H. (2000). Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies. Mol Cell Biol Res Commun. 3: 205-211.
38. Ueda T, Sasaki M, Elia AJ, Chio, Hamada K, Fukunaga R, Mak TW. (2010). Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA. 107: 13984-13990.
39. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. (1999). Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol. 19: 1871-1880.
40. Wendel HG, de Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. (2004). Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428: 332-337.
41. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW. (2006). Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 66: 7639-7646.
42. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Terua-Feldstein J, Pelletier J, Lowe SW. (2007). Dissecting eIF4E action in tumorigenesis. Genes Dev. 21: 3232-3237.
43. Zhan Y, Dahabieh MS, Rajakumar A, Dobocan MC, M?Boutchou MN, Goncalves C, Shiru LL, Pettersson F, Topisirovic I, ven Kempen L, Del Rincon SV, Miller WH Jr. (2015). The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. J Invest Dermatol. 135: 1368-1376.